9-bromo-5-carboxymethyl-6,7-dihydro-1H, 5 H-pyrido[1,2,3-de]quinoxaline-2,3-dione → HCID 178520188, 화합물

HRID 52524

반응식

HRID 52524 반응식
[Br:1][C:2]1[CH:3]=[C:4]2[CH2:16][CH2:15][CH:14]([CH2:17][C:18]([OH:20])=O)[N:6]3[C:7](=[O:13])[C:8](=[O:12])[NH:9][C:10]([CH:11]=1)=[C:5]23.[NH2:21][C:22]1[NH:26][N:25]=[N:24][N:23]=1>>[Br:1][C:2]1[CH:3]=[C:4]2[CH2:16][CH2:15][CH:14]([CH2:17][C:18](=[O:20])[NH:21][C:22]3[NH:26][N:25]=[N:24][N:23]=3)[N:6]3[C:7](=[O:13])[C:8](=[O:12])[NH:9][C:10]([CH:11]=1)=[C:5]23

참가 물질

3

반응물 2

HCID 104723389-bromo-5-carboxymethyl-6,7-dihydro-1H, 5 H-pyrido[1,2,3-de]quinoxaline-2,3-dioneHCID 178509299HCID 178509299, 화합물

생성물 1

HCID 178520188HCID 178520188, 화합물수율 84%

실험 절차

A procedure similar to that described in Example 51 was carried out with 9-bromo-5-carboxymethyl-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione (170 mg, 0.5 mmol) and aminotetrazole (50 mg, 0.59 mmol) to give 170 mg of the title compound (84%): mp 246°~247° C.; 1H NMR (270 MHz, DMSO-d6) δ12.12 (bs, 1H), 12.08 (s, 1H), 7.24 (d, 1H, J=2 Hz), 7.17 (d, 1H, J=2 Hz), 5.19~5.28 (m, 1H), 3.01 (ddd, 1H, J=17.1, 13.5, 4.5 Hz), 2.84 (dm, 1H, J=17.1 Hz), 2.66~2.75 (m, 2H), 2.12 (dm, 1H, J=13.5 Hz), 1.83~1.97 (m, 1H).

출처 및 근거

ORD 기록
ord-0ab279359dad49b4afdb0696d82fc2c8
출처 데이터셋
uspto-grants-1997_04
특허 번호
US05616586

연결된 노트

불러오는 중…